Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Neoplasms 1Hemangiosarcoma 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1

Interventions

Fulvestrant 36Specimen Handling 32Letrozole 32Paclitaxel 24pembrolizumab 19Carboplatin 19Capecitabine 19ribociclib 18exemestane 18palbociclib 17Trastuzumab 17Tamoxifen 17Magnetic Resonance Spectroscopy 17Anastrozole 16Biopsy 15trastuzumab deruxtecan 14abemaciclib 14pertuzumab 11Radiotherapy 11Cyclophosphamide 9inavolisib 8elacestrant 8olaparib 7Taxes 7Standard of Care 7Radiation 7Mastectomy, Segmental 7Goserelin 7130-nm albumin-bound paclitaxel 7giredestrant 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × 4-hydroxy-N-desmethyltamoxifen × 30 days × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡